0000899243-20-005685.txt : 20200224 0000899243-20-005685.hdr.sgml : 20200224 20200224210100 ACCESSION NUMBER: 0000899243-20-005685 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200220 FILED AS OF DATE: 20200224 DATE AS OF CHANGE: 20200224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: North Michael Paul CENTRAL INDEX KEY: 0001689925 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 20646949 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY, SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 3854 AMERICAN WAY STREET 2: SUITE A CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-20 0 0000896262 AMEDISYS INC AMED 0001689925 North Michael Paul 3854 AMERICAN WAY, SUITE A BATON ROUGE LA 70816 0 1 0 0 Chief Information Officer Common Stock 2020-02-20 4 F 0 130 194.12 D 9420 D Common Stock 2020-02-21 4 M 0 5625 32.56 A 15045 D Common Stock 2020-02-21 4 S 0 600 192.86 D 14445 D Common Stock 2020-02-21 4 S 0 3435 193.87 D 11010 D Common Stock 2020-02-21 4 S 0 1590 194.62 D 9420 D Common Stock 2020-02-21 4 M 0 3788 46.35 A 13208 D Common Stock 2020-02-21 4 S 0 441 192.84 D 12767 D Common Stock 2020-02-21 4 S 0 2000 193.84 D 10767 D Common Stock 2020-02-21 4 S 0 1347 194.57 D 9420 D Common Stock 457 I Through 401(k) Plan Stock Option (right to buy) 32.56 2020-02-21 4 M 0 5625 0.00 D 2019-06-02 2025-06-02 Common Stock 5625 0 D Stock Option (right to buy) 46.35 2020-02-21 4 M 0 3788 0.00 D 2018-01-20 2027-01-20 Common Stock 3788 1894 D The total amount of shares beneficially owned includes 1,027 shares held in an employee stock purchase plan account. These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.40 to $193.32, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.40 to $194.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.40 to $195.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.27 to $193.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.29 to $194.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.27 to $195.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4. The information in this report is based on a plan statement dated as of December 31, 2019. On January 20, 2017, the reporting person was granted an option to purchase 7,577 shares of common stock. The options are subject to time-based vesting conditions. 1,895 of the options vested on January 20, 2018, 1,894 of the options vested on January 20, 2019, 1,894 of the options vested on January 20, 2020, and 1,894 of the options will vest on January 20, 2021, provided that the reporting person remains continuously employed by the Issuer on such date, subject to prorated vesting provisions as provided in the award agreement for the stock options. The reporting person previously exercised 1,895 of the options. /s/ Jennifer R. Guckert, pursuant to a power of attorney 2020-02-24